Cony D'Cruz, Superluminal Medicines CEO & co-founder

For­mer Schrödinger ex­ec launch­es RA Cap­i­tal-backed start­up for AI drug dis­cov­ery

Su­per­lu­mi­nal Med­i­cines, a start­up claim­ing that it can use ar­ti­fi­cial in­tel­li­gence to shrink the de­vel­op­ment of pre­clin­i­cal drug can­di­dates from years to a mat­ter of months, emerged from stealth Mon­day morn­ing with $33 mil­lion in seed fund­ing.

RA Cap­i­tal Man­age­ment led the round. It’s the largest seed fund­ing for a biotech that launched this year, ac­cord­ing to da­ta pro­vid­ed by Pitch­Book. Soft­ware in­vestor In­sight Part­ners, chip­mak­er Nvidia, and LGBTQ-fo­cused ven­ture cap­i­tal firm Gain­gels chipped in as well.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

San Diego, CA, USA